Expression of histone deacetylases in diffuse large B-cell lymphoma and its clinical significance

International Journal of Medical Sciences

Volumn 11, Issue 10, 2014, Pages 994-1000

  Lee, Sung Hak ^a   Yoo, Changyoung ^b   Im, Soyoung ^b   Jung, Ji Han ^b   Choi, Hyun Joo ^b   Yoo, Jinyoung ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Diffuse large B cell lymphoma; Epigenetic; Histone deacetylase; Nodal lymphoma; Survival

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HDAC2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KOREA; LARGE CELL LYMPHOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MARGINAL ZONE LYMPHOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL TIME; TUMOR LOCALIZATION; ENZYMOLOGY; GENETIC EPIGENESIS; GENETICS; METABOLISM; MIDDLE AGED;

AGED; EPIGENESIS, GENETIC; FEMALE; HISTONE DEACETYLASE 2; HISTONE DEACETYLASES; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED;

EID: 84905456935     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.8522     Document Type: Article

References (24)

1. Jain N, Odenike O. Emerging role of the histone deacetylase inhibitor romidepsin in hematologic malignancies. Expert Opin Pharmacother. 2010; 11: 3073-84.
2. Zain J, O'Connor OA. Targeting histone deacetyalses in the treatment of Band T-cell malignancies. Invest New Drugs. 2010; 28 Suppl 1: S58-78.
3. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009; 10: 32-42.
4. Watanabe T. Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas. Expert Opin Investig Drugs. 2010; 19: 1113-27.
5. Buglio D, Younes A. Histone deacetylase inhibitors in Hodgkin lymphoma. Invest New Drugs. 2010; 28 Suppl 1: S21-7.
6. Copeland A, Buglio D, Younes A. Histone deacetylase inhibitors in lymphoma. Curr Opin Oncol. 2010; 22: 431-6.
7. Mithraprabhu S, Grigoriadis G, Khong T, et al. Deacetylase inhibition in myeloproliferative neoplasms. Invest New Drugs. 2010; 28 Suppl 1: S50-7.
8. Murawski N, Pfreundschuh M. New drugs for aggressive B-cell and T-cell lymphomas. Lancet Oncol. 2010; 11: 1074-85.
9. Giannini G, Cabri W, Fattorusso C, et al. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Med Chem. 2012; 4: 1439-60.
10. Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol. 2012; 90: 85-94.
11. Jazirehi AR. Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy. Anticancer Drugs. 2010; 21: 805-13.
12. Farnebo M, Bykov VJ, Wiman KG. The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer. Biochem Biophys Res Commun. 2010; 396: 85-9.
13. Sarita Rajender P, Ramasree D, Bhargavi K, et al. Selective inhibition of proteins regulating CDK/cyclin complexes: strategy against cancer-a review. J Recept Signal Transduct Res. 2010; 30: 206-13.
14. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC press, 2008; 158-66.
15. Horwitz SM. The Emerging Role of Histone Deacetylase Inhibitors in Treating T-cell Lymphomas. Curr Hematol Malig Rep. 2011; 6: 67-72.
16. Min SK, Koh YH, Park Y, et al. Expression of HAT1 and HDAC1, 2, 3 in Diffuse Large B-Cell Lymphomas, Peripheral T-Cell Lymphomas, and NK/T-Cell Lymphomas. Korean J Pathol. 2012; 46:142-50.
17. Marquard L, Poulsen CB, Gjerdrum LM, et al. Histone deacetylase 1, 2, 6 and acetylated histone H4 in B- and T-cell lymphomas. Histopathology. 2009; 54: 688-98.
18. Adams H, Fritzsche FR, Dirnhofer S, et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma. Expert Opin Ther Targets. 2010; 14: 577-84.
19. Marquard L, Gjerdrum LM, Christensen IJ, et al. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology. 2008; 53: 267-77.
20. Müller BM, Jana L, Kasajima A, et al. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer. 2013; 13: 215.
21. Noh JH, Chang YG, Kim MG, et al. MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer. Cancer Lett. 2013; 335; 455-62.
22. Du X, Zhao H, Zang L, et al. Overexpression of histone deacetylase 2 predicts unfavorable prognosis in human gallbladder carcinoma. Pathol Oncol Res. 2013; 19:397-403.
23. Tula-Sanchez AA, Havas AP, Alonge PJ, et al. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors. Cancer Biol Ther. 2013; 14: 949-61.
24. Cycon KA, Mulvaney K, Rimsza LM, et al. Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma. Immunology. 2013; 140: 259-72.